Overview

Bioavailability Study Comparing 10 mg Amlodipine Besylate Orally Disintegrating Tablets (ODT) And 10 mg Amlodipine Besylate Capsules

Status:
Completed

Trial end date:
2010-06-01

Target enrollment:

Participant gender:

Summary

This study is being performed to determine the bioavailability, or extent of absorption into the body, of a 10 mg amlodipine besylate orally disintegrating tablet (ODT) as compared to the bioavailability of a 10 mg amlodipine besylate capsule.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Collaborators:

Aurobindo Pharma
Aurobindo Pharma Ltd
Trident Life Sciences Ltd.

Treatments:

Amlodipine